These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 30369576)

  • 41. Meta-Analysis Comparing Direct Oral Anticoagulants Versus Warfarin in Morbidly Obese Patients With Atrial Fibrillation.
    Kido K; Shimizu M; Shiga T; Hashiguchi M
    Am J Cardiol; 2020 Jul; 126():23-28. PubMed ID: 32345473
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Trends in Oral Anticoagulant Use Among 436 864 Patients With Atrial Fibrillation in Community Practice, 2011 to 2020.
    Navar AM; Kolkailah AA; Overton R; Shah NP; Rousseau JF; Flaker GC; Pignone MP; Peterson ED
    J Am Heart Assoc; 2022 Nov; 11(22):e026723. PubMed ID: 36346063
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prescribing trends of atrial fibrillation patients who switched from warfarin to a direct oral anticoagulant.
    Hale ZD; Kong X; Haymart B; Gu X; Kline-Rogers E; Almany S; Kozlowski J; Krol GD; Kaatz S; Froehlich JB; Barnes GD
    J Thromb Thrombolysis; 2017 Feb; 43(2):283-288. PubMed ID: 27837309
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
    Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Validation of satisfaction questionnaire ACTS in outpatients with atrial fibrillation treated with oral anticoagulants in Spain. ALADIN Study].
    Suárez C; Pose A; Montero-Pérez-Barquero M; Roquer J; Gállego J; Ràfols C; Cazorla D; Vivancos J;
    Med Clin (Barc); 2016 Sep; 147(5):192-198. PubMed ID: 27423653
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 47. Higher persistence in newly diagnosed nonvalvular atrial fibrillation patients treated with dabigatran versus warfarin.
    Zalesak M; Siu K; Francis K; Yu C; Alvrtsyan H; Rao Y; Walker D; Sander S; Miyasato G; Matchar D; Sanchez H
    Circ Cardiovasc Qual Outcomes; 2013 Sep; 6(5):567-74. PubMed ID: 23922182
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Patients' Characteristics Affect the Survival Benefit of Warfarin Treatment for Hemodialysis Patients with Atrial Fibrillation. A Historical Cohort Study.
    Brancaccio D; Neri L; Bellocchio F; Barbieri C; Amato C; Mari F; Canaud B; Stuard S
    Am J Nephrol; 2016; 44(4):258-267. PubMed ID: 27598317
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Non-valvular atrial fibrillation patients with low CHADS2 scores benefit from warfarin therapy according to propensity score matching subanalysis using the J-RHYTHM Registry.
    Chishaki A; Kumagai N; Takahashi N; Saikawa T; Inoue H; Okumura K; Atarashi H; Yamashita T; Origasa H; Sakurai M; Kawamura Y; Kubota I; Matsumoto K; Kaneko Y; Ogawa S; Aizawa Y; Chinushi M; Kodama I; Watanabe E; Koretsune Y; Okuyama Y; Shimizu A; Igawa O; Bando S; Fukatani M;
    Thromb Res; 2015 Aug; 136(2):267-73. PubMed ID: 26092429
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
    Lee SI; Sayers M; Lip GY; Lane DA
    Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015.
    Kjerpeseth LJ; Ellekjær H; Selmer R; Ariansen I; Furu K; Skovlund E
    Eur J Clin Pharmacol; 2017 Nov; 73(11):1417-1425. PubMed ID: 28735494
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Net Clinical Benefit of Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Phase III Atrial Fibrillation Trials.
    Renda G; di Nicola M; De Caterina R
    Am J Med; 2015 Sep; 128(9):1007-14.e2. PubMed ID: 25910790
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study.
    Lauffenburger JC; Farley JF; Gehi AK; Rhoney DH; Brookhart MA; Fang G
    J Am Heart Assoc; 2015 Apr; 4(4):. PubMed ID: 25862791
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Perception of Patients Regarding Burdens and Benefits of Vitamin K Antagonists Among Patients with Nonvalvular Atrial Fibrillation.
    Escobar C; Barrios V; Prieto L; Lobos JM; Polo J; Vargas D
    Cardiovasc Hematol Agents Med Chem; 2018; 16(2):106-113. PubMed ID: 29879893
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany - results from the German AFNET registry.
    Haeusler KG; Gerth A; Limbourg T; Tebbe U; Oeff M; Wegscheider K; Treszl A; Ravens U; Meinertz T; Kirchhof P; Breithardt G; Steinbeck G; Nabauer M;
    BMC Neurol; 2015 Aug; 15():129. PubMed ID: 26242880
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High number of newly initiated direct oral anticoagulant users switch to alternate anticoagulant therapy.
    Manzoor BS; Walton SM; Sharp LK; Galanter WL; Lee TA; Nutescu EA
    J Thromb Thrombolysis; 2017 Nov; 44(4):435-441. PubMed ID: 29027097
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation.
    Palamaner Subash Shantha G; Bhave PD; Girotra S; Hodgson-Zingman D; Mazur A; Giudici M; Chrischilles E; Vaughan Sarrazin MS
    Circ Cardiovasc Qual Outcomes; 2017 Apr; 10(4):. PubMed ID: 28408716
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Atrial Fibrillation Patients on Warfarin and Their Transition to Direct Oral Anticoagulants.
    Collins P; Lewin A; Vincze Irving N; Sylvester K; Fanikos J; Goldhaber SZ; Connors JM
    Crit Pathw Cardiol; 2021 Jun; 20(2):103-107. PubMed ID: 33337730
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke.
    Yoon CH; Park YK; Kim SJ; Lee MJ; Ryoo S; Kim GM; Chung CS; Lee KH; Kim JS; Bang OY
    Stroke; 2014 Oct; 45(10):2983-8. PubMed ID: 25147329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.